DEC 19, 2017 3:10 PM PST

'Junk' Gene Implicated in Cancer's Growth

WRITTEN BY: Xuan Pham

Image credit: Pixabay.com

One of the biggest surprise findings from the completion of the Human Genome Project was that only 1.5 percent of our genome encodes for all of the protein-coding genes. The rest of our genome has been unfairly described as “junk” DNA.

But amidst this so-called genomic junk, scientists are finding sequences that modulate cellular processes and affect health and disease. Case in point, researchers from the University of Michigan recently discovered a ‘junk’ gene that has a “direct impact” on cancer development.

The research team began by combing the cell’s transcriptome – that is, the single-stranded RNA portion of the genetic code that’s been transcribed from DNA. Several types of RNAs make up the transcriptome. Among these is a particular molecule class known as long non-coding RNAs (lncRNAs). These transcripts are greater than 200 nucleotides but do not code for any proteins.

When the team dug further, they discovered a lncRNA that stood out from the rest. Called Testis-associated Highly-conserved Oncogenic long non-coding RNA, or THOR, this lncRNA is found in humans, mice and zebrafish. That this seemingly non-coding, “junk” gene has been evolutionarily conserved in three separate species is remarkable, and suggests there’s a biological importance associated with this lncRNA.

The team also found it curious that THOR was highly expressed in the testes and nowhere else in normal adult tissue. Yet, when they analyzed cancer tissues, particularly melanoma and lung cancer, THOR showed up in abundance.

Collectively, these lines of evidence suggest THOR is involved in cancer development in some way. Indeed, when the team modified cells to have THOR silenced, tumor growth was reduced. By contrast, when THOR is overexpressed, tumor growth was accelerated.

"If we perturb THOR function," said Dr. Arul Chinnaiyan, the study’s senior author, "we disturb the ability to stabilize RNA. This inhibits cell proliferation."

Furthermore, the effects of these alterations were not seen in normal cells, suggesting THOR may be limited to cancer cells. This would present a unique opportunity for therapy since blocking THOR would not seem to harm healthy cells.

The discovery not only helps to reinstate the importance of non-coding genomic sequences, but also has large implications for the clinical diagnosis and treatment of cancers.

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 18, 2020
Cancer
Clinical trials go forth for osteosarcoma in dogs and glioblastoma multiforme in humans using the same precision medicine
JUL 18, 2020
Clinical trials go forth for osteosarcoma in dogs and glioblastoma multiforme in humans using the same precision medicine
A development in precision medicine in cancer treatment for dogs has led to a similar advancement in cancer treatment fo ...
JUL 27, 2020
Cancer
Identifying Tumor Cells in the Blood with Artificial Intelligence
JUL 27, 2020
Identifying Tumor Cells in the Blood with Artificial Intelligence
Cancer diagnostics is an area of keen interest in the fight against cancer. Cancer often slips by routine checkups and v ...
AUG 06, 2020
Clinical & Molecular DX
Gut Feeling: Spotting the Early Signs of Gastric Cancer
AUG 06, 2020
Gut Feeling: Spotting the Early Signs of Gastric Cancer
In a study published in Science Advances, scientists propose a new method for diagnosing gastric cancer, the third leadi ...
AUG 19, 2020
Immunology
Cancer Mutation Improves Chemo Drug Performance
AUG 19, 2020
Cancer Mutation Improves Chemo Drug Performance
When it comes to cancer biomarkers, it’s often the genetic signatures that are associated with poor patient outcom ...
SEP 18, 2020
Coronavirus
How Coronavirus Spread in the US and Europe
SEP 18, 2020
How Coronavirus Spread in the US and Europe
Researchers are beginning to examine how the world's response to the pandemic virus SARS-CoV-2 went wrong, and right ...
SEP 20, 2020
Drug Discovery & Development
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
SEP 20, 2020
New Drug Combo Prolongs Survival with Advanced Kidney Cancer
Biopharmaceutical company Bristol-Myers Squibb has found that a new drug combination can reduce death rates among those ...
Loading Comments...